These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 1808136)

  • 1. The effects of contrast media on coagulation factor XII.
    Laurie AJ; Lyon SG; Lasser EC
    Invest Radiol; 1991 Nov; 26 Suppl 1():S23-5; discussion S40-1. PubMed ID: 1808136
    [No Abstract]   [Full Text] [Related]  

  • 2. Mechanism of surface-mediated activation of bovine Factor XII and prekallikrein.
    Sugo T; Ohno Y; Shimada T; Kato H; Iwanaga S
    Adv Exp Med Biol; 1983; 156():87-107. PubMed ID: 6602465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetic studies on surface-mediated activation of bovine factor XII and prekallikrein. Effects of kaolin and high-Mr kininogen on the activation reactions.
    Sugo T; Kato H; Iwanaga S; Takada K; Sakakibara S
    Eur J Biochem; 1985 Jan; 146(1):43-50. PubMed ID: 3871394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initiation of contact activation by sulfatides.
    Tans G; Griffin JH
    Adv Exp Med Biol; 1983; 156():63-72. PubMed ID: 6602464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New agents for thromboprotection. A role for factor XII and XIIa inhibition.
    Labberton L; Kenne E; Renné T
    Hamostaseologie; 2015; 35(4):338-50. PubMed ID: 25609114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Activation of the kallikrein-kinin system by intravenous administration of ionic and non-ionic radiographic contrast media].
    Hoffmeister HM; Fuhrer G; Abels GA; Pirschel J; Heller W
    Dtsch Med Wochenschr; 1988 Jul; 113(28-29):1138-41. PubMed ID: 3260554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factor XII-mediated contact activation related to poor prognosis in disseminated intravascular coagulation.
    Park HS; Gu J; You HJ; Kim JE; Kim HK
    Thromb Res; 2016 Feb; 138():103-107. PubMed ID: 26706311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surfaces and sensitivity in contrast material reactions.
    Lasser EC; Lyon SG; Petro Z
    Invest Radiol; 1991 Nov; 26 Suppl 1():S20-2; discussion S40-1. PubMed ID: 1808129
    [No Abstract]   [Full Text] [Related]  

  • 9. Activation of factor XII and prekallikrein with polysaccharide sulfates and sulfatides: comparison with kaolin-mediated activation.
    Shimada T; Sugo T; Kato H; Yoshida K; Iwanaga S
    J Biochem; 1985 Feb; 97(2):429-39. PubMed ID: 2861197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factor XII levels in patients after abdominal surgery.
    Fuhrer G; Gallimore MJ; Lambrecht M; Heller W
    Adv Exp Med Biol; 1989; 247B():509-14. PubMed ID: 2610089
    [No Abstract]   [Full Text] [Related]  

  • 11. Inhibition of activated Hageman factor (factor XIIa) by an inhibitor of the plasminogen activation (PA inhibitor).
    Hedner U; Martinsson G
    Thromb Res; 1978 Jun; 12(6):1015-23. PubMed ID: 99837
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of negatively charged activating compounds on inactivation of factor XIIa by Cl inhibitor.
    Pixley RA; Schmaier A; Colman RW
    Arch Biochem Biophys; 1987 Aug; 256(2):490-8. PubMed ID: 3497611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes of plasma activated Factor XII type A (XIIaA) concentrations following percutaneous coronary intervention (PCI).
    Pönitz V; Pritchard D; Grundt H; Mehus MB; Nilsen DW
    J Thromb Thrombolysis; 2007 Oct; 24(2):131-5. PubMed ID: 17492403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of activation of coagulation factor XI by factor XIIa studied with monoclonal antibodies.
    Akiyama H; Sinha D; Seaman FS; Kirby EP; Walsh PN
    J Clin Invest; 1986 Dec; 78(6):1631-7. PubMed ID: 3491093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural and functional characterization of factor XII.
    Tans G; Rosing J
    Semin Thromb Hemost; 1987 Jan; 13(1):1-14. PubMed ID: 3551074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of activation of the contact system of coagulation in vitro and in vivo: quantitation of activated Hageman factor-C-1-inhibitor and kallikrein-C-1-inhibitor complexes by specific radioimmunoassays.
    Nuijens JH; Huijbregts CC; Cohen M; Navis GO; de Vries A; Eerenberg AJ; Bakker JC; Hack CE
    Thromb Haemost; 1987 Aug; 58(2):778-85. PubMed ID: 2445044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factor XII: a drug target for safe interference with thrombosis and inflammation.
    Kenne E; Renné T
    Drug Discov Today; 2014 Sep; 19(9):1459-64. PubMed ID: 24993156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lower factor XII activity is a risk marker rather than a risk factor for cardiovascular disease: a rebuttal.
    Kanaji T
    J Thromb Haemost; 2008 Jun; 6(6):1053-4; author reply 1055-6. PubMed ID: 18331454
    [No Abstract]   [Full Text] [Related]  

  • 19. Fluid phase activation of Hageman factor (factor XII) in citrated human plasma by bromelain: an application to the indirect enzymatic assay for Hageman factor.
    Oh-ishi S
    Thromb Res; 1982 Sep; 27(5):619-23. PubMed ID: 6983741
    [No Abstract]   [Full Text] [Related]  

  • 20. Studies of adsorption, activation, and inhibition of factor XII on immobilized heparin.
    Sanchez J; Elgue G; Riesenfeld J; Olsson P
    Thromb Res; 1998 Jan; 89(1):41-50. PubMed ID: 9610759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.